Approval · Notice of Compliance 2539 · 2001
CAELYX: Notice of Compliance 2539
Issued January 18, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2539
- Date
- January 18, 2001
- Company
- Schering Canada Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: treatment of advanced ovarian cancer following failure of standard first-line therapy
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAELYX | Not yet assigned | — |
Medicinal ingredients
- DOXORUBICIN HYDROCHLORIDE 2 MG per ML